Business Combination (Tables)
 12 Months Ended
Dec. 31, 2021
Business Combinations [Abstract]  
Schedule of Net Proceeds From The Business Combination
The following table summarizes the elements of the net proceeds from the business combination as of December 31, 2021:
 
     Recapitalization  
Cash—MCAD cash and cash held in trust
    $ 9,485  
Cash—Proceeds from PIPE Investment
      50,000  
Less: underwriting fees and other offering costs
      (16,724 ) 
  
 
 
  
Net proceeds from business combination
    $ 42,761  
  
 
 
  
Schedule Of Number Of Shares Of Common Stock Outstanding Immediately Following Consummation Of Business Combination Transaction
The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the business transaction:
 
     Number of Shares  
MCAD shares and rights outstanding prior to the business combination
      8,152,500  
Less: redemptions of MCAD shares prior to the business combination
      (4,826,260 ) 
  
 
 
  
Common stock of MCAD
      3,326,240  
Shares issued pursuant to the PIPE including transaction related shares
      5,098,750  
  
 
 
  
Business combination and PIPE financing shares
      8,424,990  
Conversion of Legacy BTX SAFEs to Common Stock
      4,080,481  
Conversion of Legacy BTX Preferred Seed A to Common Stock
      1,010,696  
Conversion of Legacy BTX Preferred Series A to Common Stock
      4,737,454  
Conversion of Legacy BTX Common Stock into new common stock
      5,346,097  
  
 
 
  
Total shares of Better Therapeutics Common Stock outstanding immediately following the business combination
      23,599,718